{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-22-001575","form_type":"8-K","ticker":"EDSA","cik":"0001540159","company_name":"Edesa Biotech, Inc.","filed_at":"2022-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.923166+00:00","generated_at":"2026-06-27T08:23:07.728730+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Edesa Biotech reports Q1 net loss of $4.4M; Health Canada approves Phase 3 design for EB05","bullets":["Net loss $4.38M ($0.33/share) vs $2.64M ($0.26/share) a year ago; operating expenses up $2.55M.","R&D expenses increased $2.57M to $3.95M, primarily due to external clinical study and drug product costs.","Health Canada approved Phase 3 design of Phase 2/3 study for EB05 as rescue therapy for ARDS.","Phase 2b chronic Allergic Contact Dermatitis study reached enrollment milestone; pace returning to pre-pandemic.","Working capital $8.14M; cash $5.88M; subsequent equity issuance raised ~$1.19M from RBC Capital Markets."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-22-001575","json":"https://secwatch.observer/filing/0001654954-22-001575.json","markdown":"https://secwatch.observer/filing/0001654954-22-001575.md","text":"https://secwatch.observer/filing/0001654954-22-001575.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1540159/000165495422001575/0001654954-22-001575-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1540159/000165495422001575/edsa_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T08:23:07.728730+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}